Negative predictive value of procalcitonin to rule out bacterial respiratory co-infection in critical covid-19 patients.
Bacterial co-infection
C-reactive protein
Covid-19 pneumonia
Mortality
Procalcitonin
Journal
The Journal of infection
ISSN: 1532-2742
Titre abrégé: J Infect
Pays: England
ID NLM: 7908424
Informations de publication
Date de publication:
10 2022
10 2022
Historique:
received:
25
02
2022
revised:
20
06
2022
accepted:
24
06
2022
pubmed:
6
7
2022
medline:
14
9
2022
entrez:
5
7
2022
Statut:
ppublish
Résumé
Procalcitonin (PCT) and C-Reactive Protein (CRP) are useful biomarkers to differentiate bacterial from viral or fungal infections, although the association between them and co-infection or mortality in COVID-19 remains unclear. The study represents a retrospective cohort study of patients admitted for COVID-19 pneumonia to 84 ICUs from ten countries between (March 2020-January 2021). Primary outcome was to determine whether PCT or CRP at admission could predict community-acquired bacterial respiratory co-infection (BC) and its added clinical value by determining the best discriminating cut-off values. Secondary outcome was to investigate its association with mortality. To evaluate the main outcome, a binary logistic regression was performed. The area under the curve evaluated diagnostic performance for BC prediction. 4635 patients were included, 7.6% fulfilled BC diagnosis. PCT (0.25[IQR 0.1-0.7] versus 0.20[IQR 0.1-0.5]ng/mL, p<0.001) and CRP (14.8[IQR 8.2-23.8] versus 13.3 [7-21.7]mg/dL, p=0.01) were higher in BC group. Neither PCT nor CRP were independently associated with BC and both had a poor ability to predict BC (AUC for PCT 0.56, for CRP 0.54). Baseline values of PCT<0.3ng/mL, could be helpful to rule out BC (negative predictive value 91.1%) and PCT≥0.50ng/mL was associated with ICU mortality (OR 1.5,p<0.001). These biomarkers at ICU admission led to a poor ability to predict BC among patients with COVID-19 pneumonia. Baseline values of PCT<0.3ng/mL may be useful to rule out BC, providing clinicians a valuable tool to guide antibiotic stewardship and allowing the unjustified overuse of antibiotics observed during the pandemic, additionally PCT≥0.50ng/mL might predict worsening outcomes.
Sections du résumé
BACKGROUND
Procalcitonin (PCT) and C-Reactive Protein (CRP) are useful biomarkers to differentiate bacterial from viral or fungal infections, although the association between them and co-infection or mortality in COVID-19 remains unclear.
METHODS
The study represents a retrospective cohort study of patients admitted for COVID-19 pneumonia to 84 ICUs from ten countries between (March 2020-January 2021). Primary outcome was to determine whether PCT or CRP at admission could predict community-acquired bacterial respiratory co-infection (BC) and its added clinical value by determining the best discriminating cut-off values. Secondary outcome was to investigate its association with mortality. To evaluate the main outcome, a binary logistic regression was performed. The area under the curve evaluated diagnostic performance for BC prediction.
RESULTS
4635 patients were included, 7.6% fulfilled BC diagnosis. PCT (0.25[IQR 0.1-0.7] versus 0.20[IQR 0.1-0.5]ng/mL, p<0.001) and CRP (14.8[IQR 8.2-23.8] versus 13.3 [7-21.7]mg/dL, p=0.01) were higher in BC group. Neither PCT nor CRP were independently associated with BC and both had a poor ability to predict BC (AUC for PCT 0.56, for CRP 0.54). Baseline values of PCT<0.3ng/mL, could be helpful to rule out BC (negative predictive value 91.1%) and PCT≥0.50ng/mL was associated with ICU mortality (OR 1.5,p<0.001).
CONCLUSIONS
These biomarkers at ICU admission led to a poor ability to predict BC among patients with COVID-19 pneumonia. Baseline values of PCT<0.3ng/mL may be useful to rule out BC, providing clinicians a valuable tool to guide antibiotic stewardship and allowing the unjustified overuse of antibiotics observed during the pandemic, additionally PCT≥0.50ng/mL might predict worsening outcomes.
Identifiants
pubmed: 35781017
pii: S0163-4453(22)00380-2
doi: 10.1016/j.jinf.2022.06.024
pmc: PMC9245395
pii:
doi:
Substances chimiques
Biomarkers
0
Procalcitonin
0
C-Reactive Protein
9007-41-4
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
374-381Informations de copyright
Copyright © 2022 The British Infection Association. Published by Elsevier Ltd. All rights reserved.
Déclaration de conflit d'intérêts
Declaration of Competing Interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.
Références
Arch Bronconeumol. 2010 Oct;46(10):543-58
pubmed: 20832928
Intensive Care Med. 2020 May;46(5):854-887
pubmed: 32222812
Clin Microbiol Infect. 2021 Apr;27(4):520-531
pubmed: 33418017
Clin Infect Dis. 2017 Jul 15;65(2):183-190
pubmed: 28407054
Crit Care. 2020 Aug 27;24(1):525
pubmed: 32854750
Aging (Albany NY). 2020 Oct 13;12(19):18833-18843
pubmed: 33051404
Influenza Other Respir Viruses. 2019 Mar;13(2):184-190
pubmed: 30443990
F1000Res. 2021 Feb 15;10:113
pubmed: 33868645
Clin Chim Acta. 2020 Jun;505:190-191
pubmed: 32145275
Intensive Care Med. 1996 Jul;22(7):707-10
pubmed: 8844239
Lancet Reg Health Eur. 2021 Dec;11:100243
pubmed: 34751263
PLoS One. 2021 May 6;16(5):e0251170
pubmed: 33956882
BMC Infect Dis. 2018 Dec 7;18(1):637
pubmed: 30526505
J Clin Pharm Ther. 2022 Feb;47(2):243-247
pubmed: 34766357
Intensive Care Med. 2017 Jan;43(1):48-58
pubmed: 27709265
Ir J Med Sci. 2021 Nov;190(4):1649-1652
pubmed: 33453014
SAGE Open Med. 2021 Oct 11;9:20503121211050755
pubmed: 34659766
J Med Virol. 2021 Jul;93(7):4564-4569
pubmed: 33822390
Emerg Microbes Infect. 2020 Dec;9(1):1123-1130
pubmed: 32475230
Semin Respir Crit Care Med. 2021 Oct;42(5):662-671
pubmed: 34544183
Crit Care Med. 1985 Oct;13(10):818-29
pubmed: 3928249
Medicina (Kaunas). 2021 Jun 09;57(6):
pubmed: 34207689
Open Forum Infect Dis. 2022 May 01;9(5):ofac179
pubmed: 35531376
Chest. 2011 Mar;139(3):555-562
pubmed: 20930007
Intensive Care Med. 2013 Feb;39(2):165-228
pubmed: 23361625
Antimicrob Agents Chemother. 2021 Mar 18;65(4):
pubmed: 33495224
J Infect. 2016 Feb;72(2):143-51
pubmed: 26702737
New Microbes New Infect. 2021 Sep;43:100910
pubmed: 34226847
Clin Chem Lab Med. 2020 Nov 19;59(2):433-440
pubmed: 33554505
JAMA. 2012 Jun 20;307(23):2526-33
pubmed: 22797452
Indian J Hematol Blood Transfus. 2021 Oct;37(4):534-542
pubmed: 33679013
Lancet. 2010 Feb 6;375(9713):463-74
pubmed: 20097417
Lancet. 2020 Feb 15;395(10223):497-506
pubmed: 31986264
Clin Microbiol Infect. 2021 Jan;27(1):83-88
pubmed: 32745596
Crit Care Med. 2012 May;40(5):1487-98
pubmed: 22511131
Clin Infect Dis. 2020 Dec 3;71(9):2459-2468
pubmed: 32358954
J Hosp Med. 2021 Mar;16(3):142-148
pubmed: 33617431
J Med Biochem. 2020 Oct 02;39(4):500-507
pubmed: 33312067
Pneumonia (Nathan). 2021 Apr 25;13(1):5
pubmed: 33894790
Crit Care. 2004 Aug;8(4):R204-12
pubmed: 15312219
JAMA Intern Med. 2020 Jul 1;180(7):934-943
pubmed: 32167524
Ther Adv Respir Dis. 2020 Jan-Dec;14:1753466620937175
pubmed: 32615866
Curr Opin Crit Care. 2007 Oct;13(5):578-85
pubmed: 17762239
J Family Med Prim Care. 2022 Jan;11(1):123-132
pubmed: 35309657